Received Feb 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 5G23D | SC |
Kinrix SC instead of IM; This non-serious case was reported by a nurse via call center representative and described the occurrence of intramuscular formulation administered by other route in a 4-year-old male patient who received DTPa-IPV (Kinrix) (batch number 5G23D, expiry date 21-AUG-2026) for prophylaxis. On 03-FEB-2025, the patient received Kinrix (subcutaneous). On 03-FEB-2025, an unknown time after receiving Kinrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Kinrix SC instead of IM). The outcome of the intramuscular formulation administered by other route was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-FEB-2025 Registered nurse reported that a male patient received by error Kinrix subcutaneously instead of Intramuscular which led intramuscular formulation administered by other route. The reporter consented to follow up.